COVID-19-Related Burden and Risk Perception in Individuals with Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy: A Cross-Sectional Study

• Published in: Neurology and therapy 2022-09, Vol.11 (3), p.1135-1146
• Main Authors: Musche, Venja, Bäuerle, Alexander, Jahre, Lisa, Schweda, Adam, Dinse, Hannah, Moradian, Sheila, Weismüller, Benjamin, Fink, Madeleine, Wolters, Anna, Fleischer, Michael, Kleinschnitz, Christoph, Teufel, Martin, Skoda, Eva-Maria, Stettner, Mark
• Format: Article
• Language: English
• Subjects: Internal Medicine; Medicine; Medicine & Public Health; Neurology; Original Research
• ISSN: 2193-8253; 2193-6536
• DOI: 10.1007/s40120-022-00359-3

Introduction This study investigated the mental health burden of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN) during the COVID-19 pandemic in comparison to matched healthy controls. Methods The cross-sectional study included 59 patients with a diagnosis of either CIDP or MMN and 59 propensity score matched healthy controls. All participants completed a survey including demographics, distress (distress thermometer), depressive symptoms (PHQ-2), generalized anxiety (GAD-7), COVID-19-related fear, and risk perception. Additionally, patients with CIDP or MMN were asked about the frequency and type of infections since treatment initiation. Results Patients with either CIDP or MMN reported experiencing reduced frequency or no differences in infection frequency since immune medication was initiated. Regarding COVID-19, patients with CIDP or MMN rated their risk of infection similar to healthy controls, while they expected a higher probability of the occurrence of symptoms, severe course, and dying of COVID-19. They reported increased depressive symptoms, generalized anxiety, and COVID-19-related fear in comparison to healthy controls. Conclusion Despite their personal experience of reduced frequency of infection since immune medication was initiated, patients with CIDP or MMN reported increased risk perception and prevalence of depressive symptoms, generalized anxiety, and COVID-19-related fear in comparison to healthy controls. This highlights the need for evidence-driven strategies to protect the mental health of this vulnerable group.